Tag: FDA Approval
-
FDA Approves Cavhanza for Philadelphia Chromosome Positive Chronic Myeloid Leukemia
When the FDA approves a new cancer treatment, it often signals a meaningful step forward for patients who need more flexible or effective options. That is exactly what happened with Cavhanza, a newly approved orally disintegrating tablet (ODT) formulation of nilotinib for adults with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Cavhanza is designed…
-
FDA Approves Decnupaz, the First Antibody-Drug Conjugate for Blastic Plasmacytoid Dendritic Cell Neoplasm
The U.S. Food and Drug Administration has approved Decnupaz (pivekimab sunirine-pvzy), marking a major step forward for people facing blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is an extremely rare and aggressive blood cancer that has historically offered patients very few effective treatment options. With this approval, adults diagnosed with BPDCN – whether newly…
-
Datroway Receives FDA Approval for Advanced Triple‑Negative Breast Cancer: What This Breakthrough Means for Patients
Triple‑negative breast cancer, often shortened to TNBC, has long been one of the most challenging forms of breast cancer to treat. Unlike other breast cancer types, TNBC does not have the three common receptors that many modern treatments target. This means patients have historically had fewer options, and many have had to rely on chemotherapy…
-
FDA Approves Fasenra as an Under the Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome
When the FDA approves a new treatment for a rare and difficult condition, it often marks a turning point for patients who have spent years dealing with unpredictable symptoms. That is exactly what happened with the approval of Fasenra, a medication given as an under the skin shot that has now been cleared to help…
-
Icotyde – a new psoriasis treatment pill
The U.S. Food and Drug Administration has approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents 12 years and older who weigh at least 40 kg. This is notable because Icotyde is an oral, once-daily medication that targets the IL‑23 receptor, a key part of the immune pathway that…
-
FDA Approves Rybrevant Faspro: A Faster, Simpler Option for Certain Lung Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved Rybrevant Faspro, a newer formulation of the cancer drug amivantamab, offering a more convenient way to treat certain people with advanced lung cancer. While the science behind the drug is complex, the impact on patients’ daily lives is easier to understand: shorter treatment visits, fewer clinic…
-
FDA Approves Darzalex Faspro as Part of a New First‑Line Quadruplet Regimen for Multiple Myeloma
Multiple myeloma is a type of blood cancer that affects plasma cells – specialized white blood cells that help the body fight infections. For years, treatment options have steadily improved, but the newest development marks one of the most meaningful steps forward yet. The U.S. Food and Drug Administration (FDA) has approved a new four‑drug…
-
FDA Approves Exdensur: A Twice‑Yearly Shot That Could Change Life for People with Severe Asthma
Severe asthma can be frightening: sudden attacks, emergency visits, and daily limits on what you can do. On December 16, 2025, the U.S. Food and Drug Administration (FDA) approved Exdensur (depemokimab‑ulaa) as an add‑on maintenance treatment for people aged 12 and older with severe asthma characterized by an eosinophilic phenotype – a type of asthma…
-
FDA Approves Breyanzi for Relapsed or Refractory Marginal Zone Lymphoma
The U.S. Food and Drug Administration approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who have already tried at least two prior systemic therapies. This approval expands the list of cancers for which Breyanzi is authorized and gives patients a new option when other treatments have failed. In plain language: what is…
-
FDA Approves Armlupeg – New Pegfilgrastim Biosimilar
The U.S. Food and Drug Administration has approved Armlupeg™ (pegfilgrastim‑unne) as a biosimilar to Neulasta® (pegfilgrastim) for decreasing the incidence of infection manifested by febrile neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive chemotherapy, and for increasing survival after acute exposure to myelosuppressive radiation. This approval adds another pegfilgrastim biosimilar to the U.S. market and…